Tokyo, Japan

Toshiya Shiojima

This inventor holds 1 USPTO granted patent. Top assignee: Sam Research Corporation. Active years: 1998.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Toshiya Shiojima. Retrieved from https://idiyas.com/inventor/toshiya-shiojima

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 1998

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Toshiya Shiojima: Innovator in Anti-Motoneuron Disease Research

Introduction

Toshiya Shiojima is a notable inventor based in Tokyo, Japan. He has made significant contributions to the field of medical research, particularly in the development of treatments for motoneuron diseases. His innovative approach has led to the creation of a unique anti-motoneuron-disease agent.

Latest Patents

Toshiya Shiojima holds a patent for an anti-motoneuron-disease agent. This invention comprises superoxide dismutase conjugated with lecithin through chemical crosslinking, represented by the generic formula (PC-SOD). This formulation serves as an effective ingredient in combating motoneuron diseases.

Career Highlights

Shiojima is associated with Sam Research Corporation, where he continues to advance his research and development efforts. His work has garnered attention for its potential impact on treating debilitating conditions that affect motor neurons.

Collaborations

Throughout his career, Toshiya Shiojima has collaborated with esteemed colleagues, including Masao Kinoshita and Yasuo Iwasaki. These partnerships have fostered a collaborative environment that enhances innovation and research outcomes.

Conclusion

Toshiya Shiojima's contributions to the field of motoneuron disease research exemplify the importance of innovation in medical science. His patented anti-motoneuron-disease agent represents a significant step forward in the quest for effective treatments.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…